Hepatocyte growth factor promotes migration of human myeloma cells

Haematologica

Volumn 93, Issue 4, 2008, Pages 619-622

  Holt, Randi Utne ^a   Fagerli, Unn Merete ^a,b   Baykov, Vadim ^a   Rø, Torstein Baade ^a   Hov, Håkon ^a   Waage, Anders ^a,b   Sundan, Anders ^a   Børset, Magne ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cell migration; Hepatocyte growth factor; Myeloma; Stromal cell derived growth factor 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CHEMOATTRACTANT; GUANINE NUCLEOTIDE BINDING PROTEIN; INTEGRIN; LY 2940002; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SCATTER FACTOR; SH 5; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; UO 126; WORTMANNIN;

ARTICLE; BONE MARROW; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; LIGAND BINDING; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BONE MARROW; CELL LINE, TUMOR; CHEMOKINE CXCL12; CHEMOTAXIS; CYTOKINES; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; INTEGRIN ALPHA4BETA1; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PLASMA CELLS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RECOMBINANT PROTEINS; SULFONES; TUMOR CELLS, CULTURED;

EID: 42149157176     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11867     Document Type: Article

References (20)

1. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Multiple myeloma. Hematology (Am Soc Hematol Educ Program ) 2001;157-77.
2. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006;34:1289-95.
3. Johrer K, Janke K, Krugmann J, Fiegl M, Greil R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine upregulation of MCP-1. Clin Cancer Res 2004;10:1901-10.
4. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35.
5. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 2003;63:5850-8.
6. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol 2001;28:543-50.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
8. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996;88:3998-4004.
9. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002;99:1405-10.
10. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998;91:806-12.
11. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002;116:796-802.
12. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000;96:3139-46.
13. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A, et al. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 2005;90:479-88.
14. Vande BI, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004;18:976-82.
15. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007;109:3024-30.
16. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996;271:24655-61.
17. Chirgadze DY, Hepple JP, Zhou H, Byrd RA, Blundell TL, Gherardi E. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 1999;6:72-9.
18. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-36.
19. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de LP, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997;137:481-92.
20. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 2004;279:28970-8.